Abstracts tagged "immunology"

Abstract Number: 1729 • ACR Convergence 2025
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Didzis Gailis¹, Fabian T.H. Ullrich¹, Sophia Dombret¹, Rebecca Hasseli-Fräbel², Marc Schmalzing³, Torsten Witte⁴, Mara Oleszowsky⁵, Marcel Müller⁶, Karolina Gente⁷, Uta Kiltz⁸, Christof Specker⁹, Alla Skapenko¹⁰ and Hendrik Schulze-Koops¹⁰, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, LMU University Hospital, Münich, Bayern, Germany, ²Section of Rheumatology and Clinical Immunology, University Hospital Munster, Münster, Nordrhein-Westfalen, Germany, ³Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany, ⁴Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁵Private Rheumatology Practice, Köln, Nordrhein-Westfalen, Germany, ⁶The Institute for Medical Information Processing, Biometry, and Epidemiology, LMU University Hospital, München, Bayern, Germany, ⁷Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Düsseldorf, Nordrhein-Westfalen, Germany, ¹⁰LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a mainstay of cancer immunotherapy. However, their increasing use has led to more immune-related adverse events (irAEs), including rheumatic…
Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0279 • ACR Convergence 2025
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Yoshiya Tanaka¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Kazuichi Okazaki⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, melissa rosen⁹, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone¹⁰, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Kansai Medical University Kori Hospital, Osaka, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 2498 • ACR Convergence 2025
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Poulami Dey¹, Rachael Bogle², Qinmengge Li³, Olesya Plazyo⁴, Rosemary Gedert⁴, Carleigh Zahn⁴, Pei-Suen Tsou⁴, John Varga⁴, Lam Tsoi⁴, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Holland, OH, ³University of Michigan, Ypsilanti, MI, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…
Abstract Number: 2033 • ACR Convergence 2025
Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease
Guy Katz¹, Judith Ferry¹, Grace McMahon¹, Isha Jha², Claire Galand³, Fei Liu⁴, Shelia Violette⁴, Jason Campagna⁴, Ana Fernandes¹, Cory Perugino⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Q³² Bio Inc,, Waltham, MA, ⁴Q³² Bio Inc, Waltham, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Hypocomplementemia, defined as low serum C3 and/or C4 concentrations, is common in patients with IgG4-related disease (IgG4-RD). While this has historically been linked with…
Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Xingxing Zhu¹, yue Yu¹, Yangfen Li¹, Panwen wang², ying li², Chantal McCabe², shiju chen², Brenna Sharp², Amber Wolzen², Hannah Langenfeld¹, Andrew C. Hanson¹, Cynthia Crowson³, svetomir Markovic², John Davis¹, Haidong Dong², Uma Thanarajasingam¹ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 0982 • ACR Convergence 2025
Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
cristiana Sieiro¹, Juan García Herrero², Jose Ordas Martínez³, Carolina Álvarez Castro³, Alejandra López Robles³, Ronald Colindres³, Ana María Sahagún⁴ and Jose María Ruiz de Morales³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²complejo asistencial universitario de leon, León, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴University of Leon, León, Spain
Background/Purpose: Herpes zoster (HZ) is a common infection, particularly in older adults and women, and can lead to complications like neuropathic pain. The risk is…
Abstract Number: 0574 • ACR Convergence 2025
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Richard G. Langley¹, Joseph F Merola², Diamant Thaçi³, Emi Nishida⁴, Bruce Strober⁵, Richard B. Warren⁶, José M. López Pinto⁷, Christina Crater⁸, Sarah Kavanagh⁸ and Paolo Gisondi⁹, ¹Dalhousie University, Halifax, NS, Canada, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Nagoya City West Medical Center, Nagoya, Japan, ⁵Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷UCB, Madrid, Spain, ⁸UCB, Morrisville, NC, ⁹Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis;1 early identification and intervention for patients with psoriasis and risk factors (RFs) for…
Abstract Number: 0262 • ACR Convergence 2025
Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
Margaret McDaniel, Brenda Stevens, Socheath Khim, Alan Wahl, Che-Leung Law and Edward Clark, Abacus Bioscience, Seattle, WA
Background/Purpose: CD180 is a Toll-like receptor (TLR) homolog expressed on antigen-presenting cells (APCs): B cells, dendritic cells, monocytes, and macrophages. While the extracellular domain of…
Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 1381 • ACR Convergence 2024
Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Cécile Bergua¹, Marine Besnard¹, Ghenima Ahmil², Laure-Helene Ouisse², Nadège Vimond¹, Apolline Salama², Bérangère Evrard², Elise Brisebard³, Alexis Collette¹, Fréderic Blanchard⁴, Thibault Larcher³, Ronald Van Brempt¹, Benoit Le Goff⁵, Ignacio Anegon² and Carole Guillonneau¹, ¹AbolerIS Pharma, Nantes, France, Nantes, France, ²Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, ³APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, ⁴INSERM UMR1229, Nantes, France, Nantes, France, ⁵CHU Nantes, France, Nantes, France
Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…

« Previous Page
1
…
6
7
8
9
10
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].